First patient enters extension study of SPI-62
The first patient has opted to enter the open-label extension study of a Phase 2 trial testing SPI-62 in people with adrenocorticotropic hormone (ACTH)-dependent forms of Cushing’s syndrome, including Cushing’s disease. The announcement was made by SPI-62’s developer, Sparrow Pharmaceuticals, which is conducting a Phase 2 trial called…